omniture
logo
Search
大睿生物医药科技（上海）有限公司
Media Room

Latest News

rss

Rona Therapeutics Presents Phase 1 Data for RN0361, a Long-Acting APOC3-Targeting siRNA, at the American Heart Association 2025 Scientific Sessions

NEW ORLEANS, Nov. 10, 2025 /PRNewswire/ -- Rona Therapeutics, a global leader in developing next-ge...

2025-11-10 12:00 1331

Rona Therapeutics Announces IND Filing of RN3161, a Highly Potent and Durable INHBE siRNA for Obesity

SHANGHAI and SANTA BARBARA, Calif., Sept. 15, 2025 /PRNewswire/ -- Rona Therapeutics, a global lead...

2025-09-15 20:00 1469

Rona Therapeutics Announces Breakthrough Data on Potential Annual Dosing RNAi Therapy RN026 Targeting Lipoprotein(a) in The National Lipid Association (NLA) Scientific Sessions 2025

SHANGHAI, May 29, 2025 /PRNewswire/ -- Rona Therapeutics, a global leading RNA therapy company, tod...

2025-05-29 20:00 1990

Rona Therapeutics Announces NMPA Approval of IND Application for RN1871, a Novel Angiotensinogen (AGT)-Targeting siRNA Drug for Hypertension

SHANGHAI, April 21, 2025 /PRNewswire/ -- Rona Therapeutics, a biotechnology company pioneering inno...

2025-04-21 19:00 2948

Rona Therapeutics Receives IND Clearance from FDA to Initiate Phase 2 Study of RN0361: an APOC3 Targeted siRNA for Management of Hypertriglyceridemia

SHANGHAI, March 17, 2025 /PRNewswire/ -- Rona Therapeutics Inc., a global leader in RNA-targeted th...

2025-03-17 19:00 3832

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

* Single dose of RN0191 achieved up to 95% individual maximum and 87% mean maximum PCSK9 reductio...

2024-11-18 09:00 3112

Rona Therapeutics Raises $35 Million Series A+ Financing to Advance Innovative Metabolic siRNA Pipeline in Clinic and Next Generation RNA Platforms

* Financing led by LongRiver Investments with participation by new and existing global investment...

2024-07-19 12:30 4036

Rona Therapeutics and Keymed Biosciences Announce Collaboration to Discover and Develop First-in-class siRNA Therapeutics for Glomerulonephritis

SHANGHAI, May 15, 2023 /PRNewswire/ -- Rona Therapeutics, Inc ("Rona") and Keymed Biosciences ("Key...

2023-05-15 12:30 3421

Rona Therapeutics Announces Exclusive Licensing Transaction from Sanofi for its Broad siRNA Therapeutic Portfolio and Technology Platform

* Rona to advance worldwide development of Sanofi siRNA portfolio targeting liver and other tissu...

2022-07-25 12:30 3349

Rona Therapeutics Announces Completion of $33 Million Series A Financing to Advance Global Discovery and Development of RNA Therapeutics

- Funding from long-term investors to build leading delivery platform and scalable drug discovery e...

2022-04-07 12:30 3465